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Abstract
Purpose To develop a mapping algorithm for generating EQ-5D-5-level (EQ-5D-5L) utility scores from the Dermatology 
Life Quality Index (DLQI) in patients with atopic dermatitis (AD).
Methods The algorithm was developed using data from 1232 patients from four countries participating in the National Health 
and Wellness Study. Spearman’s rank correlation coefficient was used to evaluate the conceptual overlap between DLQI 
and EQ-5D-5L. Six mapping models (ordinary least squares [OLS], Tobit, three different two-part models, and a regression 
mixture model) were tested with different specifications to determine model performance and were ranked based on the sum 
of mean absolute error (MAE), and root mean squared error (RMSE).
Results The mean DLQI score was 7.23; mean EQ-5D-5L score was 0.78; and there were moderate negative correlations 
between DLQI and EQ-5D-5L scores (p = − 0.514). A regression mixture model with total DLQI, and age and sex as inde-
pendent variables performed best for mapping DLQI to EQ-5D-5L (RMSE = 0.113; MAE = 0.079).
Conclusion This was the first study to map DLQI to EQ-5D-5L exclusively in patients with AD. The regression mixture 
model with total DLQI, and age and sex as independent variables was the best performing model and accurately predicted 
EQ-5D-5L. The results of this mapping can be used to translate DLQI data from clinical studies to health state utility values 
in economic evaluations.
Keywords Mapping · Dermatology Life Quality Index (DLQI) · EuroQoL-5-dimension (EQ-5D) · Atopic Dermatitis (AD)
Introduction
Atopic dermatitis (AD) is a chronic, inflammatory skin 
condition with a wide range of symptoms affecting not 
only the skin, but also the immune system, sleep, mental 
health, and quality of life (QoL) [1]. Evidence suggests that 
AD “is the leading non-fatal health burden attributable to 
skin diseases” [2]. QoL is measured in less than 30% of 
AD studies [3], and there is no single instrument recom-
mended to measure health-related QoL (HRQL) in patients 
with AD [4], with some reviews finding up to 18 different 
measures used in AD studies [3]. Certain jurisdictions also 
have certain preferences for instruments, [5, 6] and depend-
ing on the jurisdiction and health technology assessment 
(HTA) body, utility scores may need to be mapped from 
one instrument to another. According to a systematic review, 
only 63 of 303 studies in AD assessed QoL with 21 studies 
using the Dermatology Life Quality Index (DLQI), while 
only one study used the EQ-5D [7]. The DLQI was the first 
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QoL assessment method developed specifically for derma-
tologic conditions, and it is the most widely used measure of 
patient-reported QoL outcomes in adults with AD in clinical 
trials [7–9]. Disease-specific measures such as the DLQI 
are sensitive to capturing disabilities caused by the disease 
and the impact of therapies on the disease [10], whereas 
generic preference-based measures such as the EQ-5D 
may not optimally capture important changes in disease-
specific health attributes [6]. However, generic preference-
based measures can be more sensitive than disease-specific 
measures when comparing the impact of comorbidities and 
side effects on utility values [11, 12]. Since the DLQI is 
not a preference-based measure, it cannot currently be used 
in cost–utility analysis (CUA) to capture HRQoL impacts 
when comparing interventions, which limits its applicability 
in health care resource allocation and ultimately treatment 
decision-making [6, 13–15]. Unlike the DLQI, the EQ-5D 
can be used to measure HRQoL across different diseases and 
interventions, and this standardization facilitates its use in 
economic evaluations [16]. When EQ-5D utility scores are 
absent from clinical studies, utility scores may be gener-
ated from other HRQoL measures through mapping [14]. 
Mapping consists of algorithm development, typically using 
regression modeling, to convert scores from one scale to 
another, such as DLQI to EQ-5D utilities [6, 17]. The first 
EQ-5D questionnaire that was developed consisted of three 
response levels indicating how much a disease affects certain 
aspects of a patient’s life [18]. This measure is widely used 
and have demonstrated reliability and validity [18]. A newer 
version with five response levels, the EQ-5D-5L, has been 
developed more recently [18], and crosswalk algorithms 
have been developed to convert between EQ-5D-5L and 
EQ-5D-3L [17]. In AD, as there is currently no available 
mapping algorithm to generate EQ-5D utility scores from 
DLQI scores, such an algorithm would be valuable for CUA 
of treatments for AD [15]. This paper reports the results of 
a direct mapping study that developed algorithms to map 
non-preference-based DLQI scores to preference-based EQ-
5D-5L utility scores in patients with AD.
Methods
Guidance from the Mapping onto Preference-based measures 
reporting Standards (MAPS) working group, the National 
Institute for Health and Care Excellence (NICE) Decision 
Support Unit, and the International Society for Pharmaco-
economics and Outcomes Research (ISPOR) were followed 
to ensure robust methodology [15, 19, 20].
Study design and estimation sample
The mapping study described here was based on patients 
with AD from the United States (US), United Kingdom, 
France, and Germany, who participated in the National 
Health and Wellness Survey (NHWS) in 2015 and 2016. 
The NHWS includes condition-specific questions and 
patient-reported outcomes [21, 22]. Sex, age, and race (in 
the US) were incorporated into the NHWS sampling plan 
to ensure the sample was representative of the respective 
countries’ general populations. Participants for the NHWS 
were recruited through internal and external affiliate net-
works, eNewsletter campaigns, banners, co-registration with 
MySurvey.com partners, and through opt-in email. A total 
of 9579 NHWS participants were contacted and participants 
who did not provide written informed consent to participate 
in this study and were not able to complete the survey online 
were excluded. Participants who were not excluded were 
screened and selected based on the following inclusion cri-
teria: diagnosed with AD and treated for it; currently suffer 
from mild, moderate, or severe AD according to the Patient-
Oriented SCORAD which was included in the survey; self-
reported age of ≥ 18 years or older on the NHWS; and must 
be from one of the four countries stipulated above. The 
estimation sample were chosen to fulfill quotas by disease 
severity and country, based on power calculations in order 
to include the population of interest and mimic the general 
AD population. According to the power calculations 130 or 
173 respondents would be needed in each severity group to 
provide 80% or 90% power, respectively, to detect significant 
differences between disease severity levels. Inclusion criteria 
were not met by 7476 participants, 490 did not complete 
the screening, 357 had mild AD and were excluded because 
the mild quota was filled, and an additional 24 participants 
did not complete the survey [23]. Of the 1232 respondents 
that fulfilled the inclusion criteria, 134 had mild AD, 1098 
had moderate-to-severe AD, and the sample size was suf-
ficient to power this study [24]. For the present study, the 
estimation sample only included participants that completed 
both the DLQI and EQ-5D-5L questionnaires. The survey 
for the present study consisted of questions from validated 
questionnaires about AD. Questions about demographics, 
general health, and characteristics specific to AD were also 
included. The survey took approximately 35 min to com-
plete and required answers to all questions to prevent miss-
ing data. The study was approved by the Institutional Review 
Board and Ethics Committees, and performed in accordance 
with various ethical principles [25], guidelines [26], prac-
tices [27], legislation, and regulations.
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Defining outcomes: source and target measures
For the mapping algorithm, the DLQI was the source 
measure from which utility scores for EQ-5D-5L, the 
target measure, were generated. The DLQI is a 10-item 
questionnaire that measures the impact of dermatology 
conditions and their treatments on HRQoL over the last 
one-week period [10]. DLQI items are scored from 0 to 
3 (0 = “not at all” or “not relevant”; 1 = “a little”; 2 = “a 
lot”; 3 = “very much”) across aspects/domains (symptoms, 
feelings, daily and leisure activities, work or school, per-
sonal relationships, and treatment) to determine how much 
the condition and treatment has impacted the patient’s life 
[10]. The sum of the scores for the 10 items produces a 
DLQI score between 0 and 30, with higher scores indicat-
ing greater impairment in HRQoL [10]. The EQ-5D has 
been used to quantify HRQoL across a wide range of treat-
ments and conditions and can be used to calculate quality-
adjusted life years (QALY) for economic assessments [16, 
28]. The EQ-5D consists of five dimensions (1 = Mobility; 
2 = Self-care; 3 = Usual activities; 4 = Pain/Discomfort; 
and 5 = Anxiety/Depression), and two versions (EQ-5D-3L 
and EQ-5D-5L) [16]. Each dimension of the EQ-5D-5L 
consists of 5 levels (1 = “No problems”; 2 = “Slight prob-
lems”; 3 = “Moderate problems”; 4 = “Severe problems”; 
5 = “Unable to”), with health states reported by the patient 
for the day the questionnaire is administered [28, 29].
The EQ-5D utility score is calculated by applying a 
preference-based population-specific value set with 
scores ranging from values less than 0 to 1 (negative 
values = health states considered worse than dead, with 
the specific lower bound dependent on country-specific 
mapping algorithm used; 0 = dead; and 1 = perfect health) 
[28–30]. The EQ-5D-5L was developed to address ceiling 
effects and improve sensitivity [31]. EQ-5D-5L data were 
collected from participants prior to NICE’s updated rec-
ommendation in October 2019 to not use the 5L valuation 
set due to quality assurance concerns [5]. However, a key 
objective of this work was to map DLQI to EQ-5D utili-
ties from a UK perspective, and because there is still only 
one UK 5L value set available, the value set for England 
specific to the EQ-5D-5L [30] was applied in this study. 
Based on the limitation of this value set, and because EQ-
5D-3L scores were not available, EQ-5D-3L utility scores 
were calculated from the 5L utility scores by using a well-
established crosswalk calculation proposed by Van Hout 
et al. [32] These results are presented in Online Appen-
dix E. Additionally, an interactive companion tool has 
been developed (Online Resource 1) which will facilitate 
updates to the mapping once a new UK value set becomes 
available.
Statistical analysis: exploratory data analysis—
conceptual overlap
The degree to which there is a conceptual overlap between 
the DLQI and EQ-5D measures determines the rigor of the 
mapping algorithm [15]. Conceptual overlap is character-
ized by content similarity between the HRQoL outcome 
measures, if the same elements are not captured by the two 
measures, conceptual overlap will be lacking, and mapping 
will not be able to establish a relationship between DLQI 
and EQ-5D [13, 17]. Before investigating conceptual over-
lap, the total DLQI scores and EQ-5D utility scores were 
plotted for inspection, and tested for normality, skewness, 
and kurtosis. Because EQ-5D utility scores were not nor-
mally distributed, Spearman’s rank correlation coefficients 
were calculated between the total scores and respective 
domains of DLQI, and EQ-5D-5L to determine the degree 
of conceptual overlap (Table 1). Correlation strengths (very 
weak = 0–0.19; weak = 0.20–0.39; moderate = 0.40–0.59; 
strong = 0.60–0.79; and very strong = 0.80–1.00) were 
defined before analysis took place and used to interpret the 
Spearman’s rank correlation coefficient results [33].
Modeling approaches and performance
A variety of model types and independent variables/specifi-
cations were investigated with the aim of developing a sim-
ple, yet predictive model. Six model types (ordinary least 
squares [OLS], Tobit, three different two-part models, and a 
regression mixture model) and four different model specifi-
cations were considered (Table 2) to determine which model 
could best predict, and directly map EQ-5D-5L utility scores 
from the DLQI. OLS has some limitations such as predicting 
values beyond the EQ-5D feasible range, and under- or over-
estimation of utility scores at very good or very poor health, 
respectively [17], but given its simplicity and interpretabil-
ity is frequently used in mapping [34]. Tobit models can 
censor predictions and were chosen because of the ceiling 
effect tendencies of centering values around 1 when mod-
eling EQ-5D-5L utilities [17, 35]. To address the proportion 
of utilities at full health, two-part models were investigated 
in addition to traditional one-part models. Within the two-
part models, a common first-stage logistic regression was 
used to estimate the probability of full health (disutility = 0), 
while a variety of forms were considered to model disutili-
ties in the subset of individuals not at full health. Disutili-
ties were then transformed back to utilities for comparison 
across all the mapping models. Some studies have found 
that mixture models outperformed OLS and Tobit models, 
in part because they address the multimodal distribution of 
EQ-5D values and abnormal distribution of values below 1 
[17, 36]. Therefore, regression mixture modeling was per-
formed as well. Regression mixture models aim to identify 
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subgroups or clusters within data [37]. Heterogeneity of the 
relationships between predictors and outcomes can be mod-
eled through identification of clusters within a distribution, 
and mixture models provide a semi-parametric and flexible 
approach to model “unknown distributional shapes” [36, 
38]. The number of clusters the mixture model will employ 
needs to be pre-specified [38]. The number of clusters was 
increased from one until models stopped converging, and the 
Akaike Information Criteria (AIC) and Bayesian Informa-
tion Criteria (BIC) of the models were used to determine 
the optimal number of clusters based on model fit (Online 
Appendix A). Models were fit assuming Gaussian mixture 
models. Parameter estimation was performed using the 
expectation maximization (EM) algorithm [39]. A set of 
regression parameters and accompanying standard errors 
were estimated for each cluster. Each of the six models were 
tested at four specification levels (level 1 used only the total 
DLQI score; level 2 used the total DLQI score and age and 
sex; level 3 and 4 were similar to levels 1 and 2 but used 
each of the DLQI items as categorical independent variables 
instead of the total DLQI score). Independent variables were 
limited in order to enable the algorithm to be applied to as 
many studies as possible, with as large a scope of datasets 
as possible.
Table 1  Spearman’s rank 
correlation coefficient matrix 
between DLQI and EQ-5D-5L
DLQI Dermatology Life Quality Index, EQ-5D-5L, EQ-5D-5-level
DLQI Utility score
EQ-5D-5L Mobility Self-care Usual activities Pain/discomfort Anxiety/
depres-
sion
Total score − 0.514 0.362 0.405 0.444 0.414 0.392
symptoms − 0.337 0.255 0.237 0.311 0.326 0.213
Feelings − 0.343 0.193 0.245 0.255 0.246 0.336
daily activities − 0.364 0.311 0.337 0.343 − 0.266 0.248
Clothing − 0.295 0.214 0.248 0.269 − 0.241 0.212
Social activities − 0.441 0.339 0.346 0.382 0.325 0.330
Sport − 0.310 0.241 0.258 0.328 0.272 0.171
Work and school − 0.382 0.320 0.310 0.380 0.320 0.223
Personal relationship − 0.323 0.255 0.292 0.310 0.225 0.226
Sex − 0.290 0.251 0.229 0.278 0.241 0.162
Treatment − 0.331 0.260 0.299 0.311 0.277 0.249
Table 2  Summary of model types and levels
DLQI Dermatology Life Quality Index, GLM Generalized Linear Model, OLS Ordinary Least Squares, DLQI 1 symptoms, DLQI 2 feelings, 
DLQI 3 daily activities, DLQI 4 clothing, DLQI 5 social activities, DLQI 6 sport, DLQI 7 work and school, DLQI 8 personal relationship, DLQI 
9 sex, DLQI 10 treatment
Type of model Prediction Modeling distribution
OLS Utility Normal
Tobit Utility Normal
Two-part: GLM (1)–OLS (2) Disutility Part 1: binomial, part 2: normal
Two-part: GLM (1)–OLS (2) Disutility Part 1: binomial, part 2: lognormal
Two-part: GLM (1)–GLM (2) Disutility Part 1: binomial, part 2: gamma
Regression mixture Utility Normal
Level Available data Independent variables
Level 1 Total DLQI Total DLQI
Level 2 Total DLQI, age, and sex Total DLQI, age, and sex
Level 3 DLQI items DLQI1, DLQI 2, DLQI3, DLQI4, 
DLQI5, DLQI6, DLQI7, DLQI8, 
DLQI9, DLQI10
Level 4 DLQI items, age, and sex DLQI1, DLQI 2, DLQI3, DLQI4, 
DLQI5, DLQI6, DLQI7, DLQI8, 
DLQI9, DLQI10, age, sex
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Model diagnostic criteria were used to evaluate model 
performance, specifically how well observed utility scores 
can be predicted by the mapping models, and included root 
mean squared error (RMSE) and mean absolute error (MAE) 
[40]. MAE is a linear score that assigns an equal weight to 
all observations, and it is an indication of the average size 
of the error rather than its direction; and the RMSE is more 
sensitive than the MAE to large errors/outliers, and better 
able to assess differences between model performances, with 
higher scores indicating worse model performance [15, 17, 
40]. In addition to these summary measures (RMSE, MAE), 
model fit to select the optimal number of clusters for the 
regression mixture model was described by using AIC and 
BIC [36]. The overall ranking was based on first ranking 
the models independently by RMSE and MAE, and then 
taking the average ranking of each model between these two 
criteria. R3.3.3 (R Core Team, Vienna, Austria) was used 
to estimate all regression models and additional statistical 
tests [41], apart from the mixture model for which the flex-
mix (V2.3–15) package in R (V3.6.1) was used [42].
Results
Descriptive statistics: characterizing the cohort
Descriptive statistics are presented in Table 3, and EQ-
5D-5L and DLQI scores and the relationship between these 
measures are presented in Fig. 1. The final estimation sample 
consisted of 1,232 participants with AD that completed the 
web-based survey, WITH a mean age of 48.3 years, and most 
participants were female (67%). EQ-5D-5L had a mean score 
of 0.78 and a median score of 0.83. The mean DLQI score 
was 7.23 and the median score was 5. 
Conceptual overlap
Spearman’s rank correlation coefficients between the total 
DLQI score and EQ-5D-5L utility scores and domains are 
reported in Table 1. Conceptually, EQ-5D and DLQI are 
negatively correlated (lower DLQI scores and higher EQ-5D 
utility scores indicate better health), and moderately nega-
tive correlations (EQ-5D-5L p = − 0.514) between EQ-5D 
utility scores and DLQI total scores were observed. There 
was a moderately negative correlation between EQ-5D util-
ity scores and the “Social Activities” DLQI domain (EQ-
5D-5L = − 0.441), and weak negative correlations between 
EQ-5D scores and the remaining DLQI items (p scores 
between − 0.20 and − 0.39). The highest (moderately) 
correlated EQ-5D domains with total DLQI scores were 
“Usual Activities” (0.444), “Pain/Discomfort” (0.414), and 
“Self-care” (0.405), while “Mobility” (0.362) and “Anxiety/
Depression” (0.392) were weakly correlated with the total 
DLQI scores. There was a weaker correlation between DLQI 
items and EQ-5D utility scores compared to EQ-5D dimen-
sions and total DLQI score.
Model selection and performance
Model performance is based on the mapping model pre-
dictions compared to the actual EQ-5D-5L utility scores. 
Coefficients for generating EQ-5D-5L utility scores from 
DLQI scores for the best model by level/specification are 
presented in Online Appendix B, including standard errors. 
Additionally, an app is provided in Online Resource 1 to 
assist with converting DLQI scores from de novo samples to 
EQ-5D -5L utility scores. Regression mixture models were 
on average the best models for predicting EQ-5D-5L utility 
scores from DLQI scores (Table 4). Model two, total DLQI 
with age and sex as independent variables was the best over-
all with the second lowest RMSE (0.113), and lowest MAE 
(0.079) for EQ-5D-5L. The regression mixture model with 
total DLQI, and age and sex as independent variables pre-
dicted EQ-5D-5L values ranging from 0.071 to 0.969. There 
was a drastic increase in both AIC and BIC when moving 
from one to two clusters for all models, but fit worsened 
overall and inconsistency between models increased when 
moving to more than two clusters. Therefore, it was deter-
mined that two clusters were optimal. Cluster sizes tended to 
be consistent between all models, with approximately 80% 
of the observations falling in cluster 1 and 20% in cluster 2. 
The larger cluster contained the larger EQ-5D values and 
tended to fit the data very well, while the smaller cluster 
Table 3  Summary of descriptive statistics of the final sample




sample (out of 
9759)
Respondents (n) 1232
Age (mean ± SD) 48.28 ± 14.98
Women (proportion) 67.37%




 Shapiro Wilk p value < 2.2e−16




 Shapiro Wilk p value < 2.2e−16
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was widely spread out among the smaller observations and 
fit the data quite poorly. Due to the multimodal nature of 
the distribution of the EQ-5D values, allowing separate sets 
of parameters to be fit to different parts of the data vastly 
improved the model fit compared to forcing all the data to 
be described by a single set of parameters. The proportion of 
predictions within ± 0.05, ± 0.10, and ± 0.15 of the observed 
EQ-5D-5L utility scores is reported in Online Appendix C to 
Fig. 1  EQ-5D-5L and DLQI scores and the relationship between 
these measures. a Probability distributions for the EQ-5D-5-level 
(EQ-5D-5L) utility scores and the Dermatology Life Quality Index 
(DLQI) scores. b Scatter plot of the EQ-5D-5L utility scores and 
DLQI scores where size of points corresponds to the number of 
observations
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provide more information about the predictive ability of the 
models. Errors were more prominent in the lower range of 
the data (− 0.25, 0.5) compared to the higher values (0.5, 1). 
Figure 2 demonstrates the predictive ability of the regression 
mixture model with total DLQI with age and sex as inde-
pendent variables, where 38.96% of the EQ-5D-5L predic-
tions were within ± 0.05 of the observed values, and 74.11% 
EQ-5D-5L were within ± 0.10. Figure 2 is a graphical repre-
sentation of model performance—predicted versus observed 
EQ-5D utility scores—with element B of the figure showing 
the range in predicted vs. observed values, and element C 
showing error distribution. The two-part models were the 
only models that predicted values below 0 and values of 1 
(perfect health). The regression mixture models at all levels 
had the most predictions within ± 0.05, ± 0.10, and ± 0.15, 
and were higher ranked at each level than the OLS, Tobit, 
and Two-part models.
Uncertainty
Variance–covariance matrices were calculated and reported 
in Online Appendix D for all independent variables from 
the highest ranked model for each level to account for the 
uncertainty associated with direct mapping, and allow for 
probabilistic sensitivity analysis in a CUA [20]. The stand-
ard error of coefficients can be calculated from the vari-
ance–covariance matrix and used in combination with the 
coefficients, and model types and specifications to character-
ize the distribution of model inputs required for probabilistic 
sensitivity analysis [20].
Table 4  Model performance for 
each models and level
DLQI Dermatology Life Quality Index, EQ-5D-5L EQ-5D-5-level, GLM Generalized Linear Model, MAE 
mean absolute error, ME mean error, OLS Ordinary Least Squares, RMSE root mean squared error, SD 
standard deviation
Regression type Mean SD EQ-5D-5L
Min Max RMSE MAE Rank
Observed EQ-5D-5L 0.777 0.2097 − 0.285 1
Total DLQI
 OLS 0.776 0.112 0.366 0.907 0.178 0.127 12
 Tobit 0.791 0.122 0.342 0.933 0.178 0.124 11
 Two-part: GLM (logistic)–OLS (normal) 0.793 0.202 − 0.029 1.424 0.266 0.198 20
 Two-part: GLM (logistic)–OLS (lognormal) 0.816 0.128 0.304 1 0.230 0.158 13
 Two-part: GLM (logistic)–GLM (gamma) 0.825 0.142 − 0.167 1 0.253 0.180 17
 Regression mixture 0.794 0.158 0.108 0.933 0.113 0.080 2
Total DLQI + age + sex
 OLS 0.776 0.116 0.342 0.972 0.175 0.125 10
 Tobit 0.791 0.127 0.313 1.010 0.176 0.123 9
 Two-part: GLM (logistic)–OLS (normal) 0.793 0.202 0.046 1.313 0.266 0.198 20
 Two-part: GLM (logistic)–OLS (lognormal) 0.816 0.128 0.244 1 0.230 0.158 13
 Two-part: GLM (logistic)–GLM (gamma) 0.818 0.150 − 0.071 1 0.257 0.186 18
 Regression Mixture 0.794 0.161 0.071 0.969 0.113 0.079 1
DLQI items
 OLS 0.776 0.130 0.233 1.012 0.165 0.118 8
 Tobit 0.790 0.141 0.228 1.079 0.166 0.117 5
 Two-part: GLM (logistic)–OLS (normal) 0.793 0.202 − 0.063 1.335 0.266 0.198 20
Two-part: GLM (logistic)–OLS (lognormal) 0.816 0.128 0.210 1 0.230 0.158 13
Two-part: GLM (logistic)–GLM (gamma) 0.818 0.160 − 0.792 1 0.260 0.181 18
Regression mixture 0.790 0.163 0.140 0.994 0.113 0.083 4
DLQI items + age + sex
 OLS 0.776 0.131 0.220 1.003 0.164 0.118 5
 Tobit 0.791 0.142 0.218 1.070 0.166 0.117 5
 Two-part: GLM (logistic)–OLS (normal) 0.793 0.202 0.007 1.319 0.266 0.198 20
 Two-part: GLM (logistic)–OLS (lognormal) 0.816 0.128 0.182 1 0.230 0.158 13
 Two-part: GLM (logistic)–GLM (gamma) 0.820 0.168 − 0.809 1 0.267 0.187 24
Regression mixture 0.791 0.163 0.085 0.996 0.112 0.082 2
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Face validity
Most coefficients had expected signs, reflecting a relationship 
in which worse health as measured by the DLQI was associ-
ated with lower utility scores for EQ-5D-5L [15]. When the 
overall DLQI score was considered in the level 1 and 2 models, 
this expected relationship held consistently. In the level 3 and 
4 models for which the DLQI items were used as independ-
ent variables, there were several examples of a worse score 
indicating better health for individual items. However, in all 
such cases, coefficients were relatively small in magnitude and 
none were statistically significant, indicating that the models 
were likely describing a lack of association rather than a true 
implausible relationship. Additionally, there was one case of 
inconsistency, where a patient indicated debilitating skin prob-
lems on the DLQI (DLQI = 30) but indicated perfect health on 
the EQ-5D-5L (EQ-5D-5L = 1).
Discussion
In this study, mapping algorithms were developed to gener-
ate EQ-5D-5L utility scores from DLQI total scores or item 
scores (with/without age and sex as independent variables) 
in patients with AD. RMSE and MAE were used to rank 24 
models (4 levels of input for 6 model types) according to 
their ability to predict EQ-5D-5L utility scores from DLQI 
data. The best performing model with the highest aver-
age accuracy for predicting EQ-5D-5L utility scores was a 
regression mixture model with total DLQI plus age and sex 
as independent variables.
This study primarily included patients with moderate-
to-severe AD and the algorithm developed in this study 
is therefore only applicable to similar populations. To the 
knowledge of the authors, this is the first study to map from 
DLQI to EQ-5D-5L exclusively in patients with AD. While 
Fig. 2  Graphical representation of model performance depicting EQ-
5D-5L observed versus predicted values. a Range of predictions for 
observed and predicted EQ-5D-5-level (EQ-5D-5L) utilities. b Scat-
ter plot of the range of predictions for observed versus predicted EQ-
5D-5L utility values. c Histogram representing error distribution of 
the observed versus predicted EQ-5D-5L utility values
2537Quality of Life Research (2020) 29:2529–2539 
1 3
previous studies have developed mappings from DLQI to 
EQ-5D-3L, they have been restricted to linear regression 
methods in populations with psoriasis [43–46]. Davison 
et al. investigated different mapping models in patients with 
psoriasis, and found that an OLS model with DLQI items, 
age, and sex was the best performing model to map from 
DLQI to EQ-5D-3L [13]. Ali et al. used an ordinal logistic 
regression (OLR) model, based on MAE and mean square 
error (MSE), and utilized response mapping from DLQI to 
EQ-5D-3L in patients with various dermatologic conditions 
(6.7% of patients had AD) [47]. The ranges of the EQ-5D-3L 
and EQ-5D-5L are different, which causes the ME, MAE, 
and RMSE to vary as they are absolute measures that depend 
on the total range of values. Therefore, it is not feasible to 
compare the EQ-5D-5L models in this study with the EQ-
5D-3L models in the study by Ali et al. Ali et al. applied 
the UK tariff value set [47], and there were differences in 
population that should be considered. The study sample in 
Ali et al. was more heterogeneous (multiple skin conditions 
and participants from 13 countries) [47] which might have 
resulted in large in-sample variations, making direct com-
parisons challenging.
This study provides new information about the relation-
ship between DLQI and EQ-5D-5L utility scores, and the 
coefficients necessary to calculate these utility scores, allow-
ing studies that have only collected DLQI data to be included 
in CUA. The models that were developed included different 
model levels, which enabled the use of different information 
sources (total DLQI, DLQI items, age, and sex) to predict 
EQ-5D utility scores. Information sources were selected 
based on relevance and availability (from publications and 
clinical studies) so the algorithms could be applied more 
widely.
Limitations included inconsistencies in answers 
between the DLQI and EQ-5D-5L questionnaires. One 
participant reported debilitating skin problems on the 
DLQI but perfect health on the EQ-5D-5L, and it is 
unlikely that their AD did not affect their general HRQoL. 
To avoid selection bias, these data were included in the 
analysis. The opposite was also true for some participants, 
and this could be explained by comorbidities. Participants 
with comorbidities were not excluded, and many partici-
pants had AD-related and non-AD-related comorbidities. 
Comorbid conditions can decrease HRQoL on the EQ-
5D-5L [48], but is unlikely to affect the DLQI, therefore, 
it may weaken the correlation between EQ-5D and DLQI. 
However, excluding participants with comorbidities may 
make the study sample less representative of the general 
AD population, which is likely to have comorbidities 
[49, 50]. Additionally, because different HRQoL aspects 
are measured by the EQ-5D and DLQI, they are com-
plementary, with the DLQI more sensitive to changes in 
clinical outcomes related to AD that can affect HRQoL, 
and the EQ-5D being more broad to allow comparisons of 
HRQoL between different diseases and taking the effects 
of comorbidities into consideration [48]. Misinterpreta-
tion or misunderstandings while responding to surveys is 
a fundamental limitation [51]. The best performing models 
were able to accurately predict the mean EQ-5D-5L. One 
limitation of mixture models is that there is a risk that 
clusters can be over extracted if outlier or non-normality is 
present [36]. However, the number of clusters in this study 
was pre-specified at two, and the response variable was 
almost completely contained between 0 and 1. Therefore, 
there was little chance that outliers were present in this 
space. Another limitation surrounding mixture models is 
the additional complexity needed to estimate multiple sets 
of parameters for each cluster [42]. Finally, predictions 
using the mixture models are most appropriate when used 
at a population or subgroup level and have limited utility 
when used to predict at the individual level [37, 38, 52].
Future extensions of this work could include mapping 
algorithms for additional country-specific EQ-5D utility 
value sets, to develop algorithms applicable to other popu-
lations. In addition, when suitable datasets become avail-
able mapping between DLQI and EQ-5D-5L in patients 
with different levels of AD severity will be investigated, 
as well as external validation of the results described here 
based on an alternative data source (NCT03725722) [53] 
that includes both DLQI and EQ-5D for individuals with 
AD. Other models (i.e., non-regression) could also be 
explored in mapping from DLQI to EQ-5D [54].
Conclusions
It is preferable to use utilities derived from directly admin-
istering the EQ-5D-3L or EQ-5D-5L, but mapping algo-
rithms are useful when these data are not available. This 
study developed mapping algorithms that can be used to 
predict EQ-5D-5L utility scores from DLQI scores with 
reasonable accuracy in patients with moderate-to-severe 
AD. The mapping model with the best predictive ability 
was the regression mixture model with total DLQI plus 
age and sex as independent variables. This was the first 
study of its kind exclusively in patients with AD, and this 
mapping algorithm can be used in economic evaluations 
to calculate EQ-5D-5L utility scores when they are una-
vailable in order to determine the impact of treatments for 
AD on QALY and assist HTAbodies by determining the 
economic value of treatments.
Funding This study was sponsored by Leo Pharma.
2538 Quality of Life Research (2020) 29:2529–2539
1 3
Compliance with ethical standards 
Conflict of interest Author A (AWV) was sponsored by Leo Pharma 
and is an employee of Leo Pharma. Author B (NK) and author C (JHP) 
are employees of Leo Pharma. None of the authors have any conflict 
of interest to declare.
Ethical approval The study was approved by the Ethics Committee/
Institutional Review Board (IRB)/Independent Ethics Committee 
(IEC), and performed in accordance with various ethical principles 
[25], guidelines [26], practices [27], legislation, and regulations. All 
procedures performed in studies involving human participants were 
in accordance with the ethical standards of the institutional and/or 
national research committee and with the 1964 Helsinki declaration 
and its later amendments or comparable ethical standards.
Informed consent Written informed consent was obtained from all 
individual participants included in the study.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. Barbarot, S., Auziere, S., Gadkari, A., Girolomoni, G., Puig, L., 
Simpson, E., et al. (2018). Epidemiology of atopic dermatitis 
in adults: Results from an international survey. Allergy, 73(6), 
1284–1293. https ://doi.org/10.1111/all.13401 .
 2. Weidinger, S., & Novak, N. (2016). Atopic dermatitis. Lancet, 
387, 1109–1122.
 3. The Economist Intelligence Unit. (2018). A misunderstood skin 
disease: Mapping the policy response to atopic dermatitis. 
Retrieved July 3, 2019 from https ://eiupe rspec tives .econo mist.
com/sites /defau lt/files /A%20mis under stood %20ski n%20dis ease_
Mappi ng%20the %20pol icy%20res ponse %20to%20ato pic%20der 
matit is.pdf.
 4. Chalmers, J., Thomas, K., Apfelbacher, C., Williams, H., Prinsen, 
C., Spuls, P., et al. (2018). Report from the fifth international con-
sensus meeting to harmonize core outcome measures for atopic 
eczema/dermatitis clinical trials (HOME initiative). BJD, 178, 
e332–2341.
 5. NICE. (2019). Position statement on use of the EQ-5D-5L value 
set for England (updated October 2019). Retrieved Feburary 3, 
2020 from https ://www.nice.org.uk/about /what-we-do/our-progr 
ammes /nice-guida nce/techn ology -appra isal-guida nce/eq-5d-5l.
 6. Canadian Agency for Drugs and Technologies in Health. (2017). 
Guidelines for the Economic Evaluation of Health Technologies. 
Retrieved November 20, 2018 from https ://www.cadth .ca/sites /
defau lt/files /pdf/guide lines _for_the_econo mic_evalu ation _of_
healt h_techn ologi es_canad a_4th_ed.pdf.
 7. Heinl, D., Chalmers, J., Nankervis, H., & Apfelbacher, C. (2016). 
Quality of life instruments used and their relation to patient-
reported outcomes: A systematic review. Acta Dermato Venere-
ology, 96(5), 596–605.
 8. Basra, M., Fenech, R., Gatt, R., Salek, M., & Finlay, A. (2008). 
The Dermatology Life Quality Index 1994–2007: A compre-
hensive review of validation data and clinical results. BJD, 159, 
997–1035.
 9. Cardiff University. (2018). Dermatology Quality Life Index 
(DLQI). Retrieved November 20, 2018 from https ://sites .cardi 
ff.ac.uk/derma tolog y/quali ty-oflif e/derma tolog y-quali ty-of-life-
index -dlqi/.
 10. Finlay, A., & Khan, G. (1994). Dermatology Life Quality Index 
(DLQI): A simple practical measure for routine clinical use. Clini-
cal and Experimental Dermatology, 19(3), 210–216.
 11. Versteegh, M., Leunis, A., Uyl-de Groot, C., & Stolk, E. (2012). 
Condition-specific preference-based measures: Benefit or burden? 
Value in Health, 15, 504–513.
 12. Rowen, D., Brazier, J., Ara, R., & Zouraq, I. (2017). The role of 
condition-specific preference-based measures in health technology 
assessment. PharmacoEconomics, 35(Suppl 1), S33–S41.
 13. Davison, N., Thompson, A., Turner, A., Longworth, L., McEl-
hone, K., Griffiths, C., et al. (2018). Generating EQ-5D-3L util-
ity scores from the Dermatology Life Quality Index: A mapping 
study in patients with psoriasis. Value in Health, 21, 1010–1018.
 14. NICE. (2013). Guide to the methods of technology appraisal 2013. 
Retrieved November 20, 2018 from https ://www.nice.org.uk/proce 
ss/pmg9/resou rces/guide -to-the-metho ds-of-techn ology -appra isal-
2013-pdf-20079 75843 781.
 15. Petrou, S., Rivero-Arias, O., Dakin, H., Longworth, L., Oppe, M., 
Froud, R., et al. (2015). The MAPS reporting statement for stud-
ies mapping onto generic preference-based outcome measures: 
Explanation and elaboration. PharmacoEconomics, 33, 993–1011.
 16. EuroQoL. (2018). EuroQoL instruments. Retrieved November 20, 
2018 from https ://euroq ol.org/eq-5d-instr ument s/.
 17. Longworth, L., & Rowen, D. (2013). Mapping to Obtain EQ-5D 
utility values for use in NICE health technology assessments. 
Value in Health, 16, 202–210.
 18. Bucholz, I., Janssen, M., Kohlman, T., & Feng, Y. (2018). A sys-
tematic review of studies comparing the measurement properties 
of the three-level and five-level versions of the EQ-5D. Pharma-
coEconomics, 36, 645–661.
 19. Longworth, L., & Rowen, D. (2011). NICE DSU technical support 
document 10: The use of mapping methods to estimate health state 
utility values. Retrieved November 20, 2018 from https ://www.
niced su.org.uk.
 20. Wailoo, A., Hernandez-Alava, M., Manca, A., Meija, A., Ray, 
J., Crawford, B., et al. (2017). Mapping to Estimate health-state 
utility from non-preference-based outcome measures: An ISPOR 
good practices for outcomes research task force report. Value in 
Health, 20, 18–27.
 21. Kantar Health. (2016). National Health and Wellness Survey. 
Retrieved November 20, 2018 from www.kanta rheal th.com.
 22. Health Economics (2017). National Health and Wellness Survey. 
Retrieved December 5, 2018 from https ://www.healt hecon omics 
.com/resou rce/natio nal-healt h-and-welln esssu rvey.
 23. Nyberg, F. (2017). Observational study report characterization 
of moderate-severe atopic dermatitis disease severity and burden 
in moderate-to-severe AD. A non-interventional cross-sectional 
burden of disease study among adults with AD in France, Ger-
many, UK, and USA.
 24. Nyberg, F., Varol, N., & Hansen, J. (2017). Greater severity of 
atopic dermatitis is associated with poorer patient-reported out-
comes among adults with moderate-to-severe atopic dermatitis. 
Paper presented at the The European Academy of Dermatology 
2539Quality of Life Research (2020) 29:2529–2539 
1 3
and Venereology (EADV) Congress, Geneva, Switzerland, Sep-
tember 13–17, 2017
 25. World Medical Association (2018, July 9th). WMA declaration of 
Helsinki: Ethical principles for medical research involving human 
subjects. Retrieved February 5, 2018 from https ://www.wma.net/
polic ies-post/wma-decla ratio n-of-helsi nki-ethic al-princ iples -for-
medic al-resea rch-invol ving-human -subje cts/.
 26. International Council for Harmonization (ICH) (1996). ICH Har-
monised Tripartite Guideline. Retrieved February 14, 2019 from 
https ://www.ich.org/filea dmin/Publi c_Web_Site/ICH_Produ cts/
Guide lines /Effic acy/E6/E6_R1_Guide line.pdf. Accessed Feb 14 
2019.
 27. Altpeter, E., Burnand, B., Capkun, G., et al. (2005). Essentials of 
good epidemiological practice. Sozial- und Praventivmedizin, 50, 
12–27.
 28. van Reenen, M., & Janssen, B. (2015). EQ-5D-5L User Guide: 
Basic information on how to use the EQ-5D-5L instrument. (Ver-
sion 2.1 ed.).
 29. van Reenen, M., & Oppe, M. (2015). EQ-5D-3L User Guide: 
Basic information on how to use the EQ-5D-3L instrument. (Ver-
sion 5.1 ed.).
 30. Devlin, N., Shah, K., Feng, Y., Mulhern, B., & van Hout, B. 
(2017). Valuing health-related quality of life: An EQ-5D-5L value 
set for England. Health Economics, 1, 16.
 31. EuroQoL. (2017). EQ-5D-5L/About. Retrieved July 3, 2019 from 
https ://euroq ol.org/eq-5d-instr ument s/eq-5d-5l-about /. Accessed 
July 3 2019.
 32. Van Hout, B., Janssen, M., Feng, Y., Kohlman, T., Busschback, 
J., Golicki, D., et al. (2012). Interim scoring for the EQ-5D-5L: 
Mapping the EQ-5D-5L to EQ-5D-3L value sets. Value in Health, 
15, 708–715.
 33. BMJ. (2018). 11. Correlation and regression. Retrieved November 
20, 2018 from https ://www.bmj.com/about -bmj/resou rces-reade rs/
publi catio ns/stati stics -squar e-one/11-corre latio n-and-regre ssion .
 34. Brazier, J., Yang, Y., Tsuchiya, A., & Rowen, D. (2010). A review 
of studies mapping (or cross walking) non-preference based meas-
ures of health to generic preference-based measures. European 
Journal of Health Economics, 11(2), 215–225.
 35. Rowen, D., Brazier, J., & Roberts, J. (2009). Mapping SF-36 onto 
the EQ-5D index: How reliable is the relationship. Health and 
Quality of Life Outcomes, 7, 1–9.
 36. Hernández Alava, M., Wailoo, A., & Ara, R. (2012). Tails from 
the peak district: Adjusted limited Dependent Variable Mixture 
Models of EQ-5D questionnaire health state utility values. Value 
in Health, 15, 550–561.
 37. Mueller, S. (2019). Mixture Modeling: Mixture of Regressions. 
Retrieved December 5, 2019 from https ://pages .mtu.edu/~shane 
m/psy52 20/daily /Day19 /Mixtu re_of_regre ssion s.html.
 38. Lamont, A., Vermunt, J. K., & Van Horn, M. L. (2016). Regres-
sion mixture models: Does modeling the covariance between 
independent variables and latent classes improve the results? 
Multivariate Behave Research, 51(1), 35–52. https ://doi.
org/10.1080/00273 171.2015.10950 63.
 39. Dempster, A., Laird, N., & Rubin, D. (1977). Maximum likelihood 
from incomplete data via the EM algorithm. Journal of the Royal 
Statistical Society, 39(1), 1–38.
 40. Chai, T., & Draxler, R. (2014). Root mean square error (RMSE) or 
mean absolute error (MAE)? Arguments against avoiding RMSE 
in the literature. Geosci Model Dev, 7, 1247–1250.
 41. Team, R. C. (2008). R: A language and environment for statistical 
computing.
 42. Grün, B., & Leisch, F. (2008). FlexMix Version 2: Finite mixtures 
with concomitant variables and varying and constant parameters. 
Journal of Statistical Software, 28(4), 1–35.
 43. Blome, C., Beikert, F., & Rustenbach, S. (2013). Mapping DLQI 
on EQ-5D in psoriasis: transformation of skin-specific health-
related quality of life into utilities. Archives of Dermatological 
Research, 305, 197–204.
 44. Currie, C., & Conway, P. (2007). PSK11: Evaluation of the asso-
ciation between EQ-5D utlity and dermatology life quality index 
(DLQI) score in patients with psoriasis. Value in Health, 10, 
A470–471.
 45. Heredi, E., Rencz, F., Balogh, O., Gulacsi, L., Herszenyi, K., 
Hollo, P., et  al. (2014). Exploring the relationship between 
EQ-5D, DLQI and PASI, and mappi EQ-5D utilities: A cross-
sectional study in psoriasis from Hungary. European Journal 
Health of Economic, 1, S111–119.
 46. Norlin, J., Steen, C., Persson, U., & Schmitt-Egenolf, M. (2012). 
Analysis of three outcome measures in moderate to severe pso-
riasis: A registry-based study of 2450 patients. British Journal of 
Dermatology, 166(4), 797–802.
 47. Ali, F., Kay, R., Finlay, A., Piguet, V., Kupfer, J., Dalgard, F., 
et al. (2017). Mapping of the DLQI scores to EQ-5D utility values 
using ordinal logistic regression. Quality of Life Research, 26, 
3025–3034.
 48. Tennvall, G., Norlin, J., Malmberg, I., Erlendsson, A., & Haed-
ersdal, M. (2015). Health related quality of life in patients with 
actinic keratosis: an observational study of patients treated in der-
matology specialist care in Denmark. Health and Quality of Life 
Outcomes, 13, 111. https ://doi.org/10.1186/s1295 5-015-0295-4.
 49. Paller, A., Jaworski, J., Simpson, E., Boguniewics, M., Russel, J., 
Block, J., et al. (2018). Major comorbidities of atopic dermatitis: 
Beyond allergic disorders. American Journal of Clinical Derma-
tology, 19(6), 821–838.
 50. Brunner, P., Silverberg, J., Guttman-Yasky, E., Paller, A., 
Kabashima, K., & Amagai, M. (2017). Increasing comorbidities 
suggests that atopic dermatitis is a systemic disorder. Journal of 
Investigative Dermatology, 137, 18–25.
 51. Bryman, A., & Bell, E. (2014). Business research methods. 
Retrieved May 22, 2018 from https ://books .googl e.dk/books 
/about /Busin ess_Resea rch_Metho ds.html?id=l7u6B wAAQB 
AJ&redir _esc=y.
 52. Van Horn, M., Smith, J., Fagan, A., et al. (2012). Not quite nor-
mal: Consequences of violating the assumption of normality in 
regression mixture models. Struct Equ Modeling, 19(2), 227–249. 
https ://doi.org/10.1080/10705 511.2012.65962 2.
 53. ClinicalTrials.gov. (2019). Dose-ranging Trial to Evaluate Del-
gocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib 
Cream Vehicle Over an 8-week Treatment Period in Adult Sub-
jects With Atopic Dermatitis. Retrieved July 19, 2019 from https 
://clini caltr ials.gov/ct2/show/NCT03 72572 2?term=delgo citin 
ib&cond=atopi c+derma titis &rank=1.
 54. Wee, H., Yeo, K., Chong, K., et al. (2018). Mean rank, equipercen-
tile, and regression mapping of world health organization quality 
of life brief (WHOQOL-BREF) to EuroQoL 5 dimensions 5 levels 
(EQ-5D-5L) utilities. Medical Decision Making, 38(3), 319–333. 
https ://doi.org/10.1177/02729 89X18 75689 0.
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
